Ivabradina Kern Pharma (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a lower resting heart rate without decreasing the strength of cardiac contraction.

The specific dose of Ivabradina Kern Pharma is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. Dosage adjustments are made during treatment to achieve the target heart‑rate range while monitoring for side effects.

Safety data for ivabradine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ivabradine lowers heart rate by targeting the If current, whereas beta‑blockers reduce heart rate through β‑adrenergic blockade. Ivabradine does not affect myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or insufficient, but it is often used in combination with beta‑blockers for additive effect.

Store Ivabradina Kern Pharma tablets at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light, and avoid storing it in areas with high humidity or extreme temperature fluctuations.

Ivabradina Kern Pharma is taken orally, usually with a glass of water. The tablets should be swallowed whole and not split, chewed, or crushed, unless the prescribing information specifically allows it. Dosing times are generally spaced evenly to maintain consistent blood levels.

Serious risks include symptomatic bradycardia, atrioventricular block, severe hypotension, and rare visual disturbances such as luminous phenomena or vision loss. Patients should be monitored for these events, especially during dose titration or when combined with other heart‑rate‑lowering agents.

Ivabradina Kern Pharma is contraindicated in patients with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or those with a resting heart rate below 50 beats per minute. It should also be avoided in individuals taking strong CYP3A4 inhibitors unless dosage adjustments are made under medical supervision.